Duloxetin Teva B.V.: Uses, Dosage & Side Effects
A serotonin-norepinephrine reuptake inhibitor (SNRI) for the treatment of depression, generalized anxiety disorder, diabetic neuropathic pain, and fibromyalgia
Duloxetin Teva B.V. contains the active substance duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Duloxetine works by increasing the levels of two key neurotransmitters—serotonin and norepinephrine—in the brain and spinal cord, which helps regulate mood, emotional processing, and pain perception. Available as gastro-resistant capsules in 30 mg and 60 mg strengths, Duloxetin Teva B.V. is a generic formulation bioequivalent to the originator product, offering the same therapeutic efficacy and safety profile at a more accessible cost. Treatment should always be initiated and monitored by a healthcare professional experienced in the management of these conditions.
Quick Facts: Duloxetin Teva B.V.
Key Takeaways
- Duloxetin Teva B.V. (duloxetine) is an SNRI antidepressant approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
- The usual therapeutic dose is 60 mg once daily, taken with or without food. Treatment typically begins at 30 mg once daily for at least two weeks before increasing to the full dose to improve tolerability.
- Nausea is the most common side effect, occurring in approximately 23% of patients, but usually improves within the first few weeks of treatment. Other common effects include dry mouth, constipation, fatigue, and dizziness.
- Duloxetine must never be stopped abruptly due to the risk of discontinuation syndrome (including dizziness, nausea, headache, and electric shock-like sensations). Gradual dose tapering over at least 2 weeks is recommended.
- Important contraindications include concomitant use with MAO inhibitors, uncontrolled narrow-angle glaucoma, severe hepatic impairment, severe renal impairment (creatinine clearance <30 mL/min), and concomitant use with potent CYP1A2 inhibitors such as fluvoxamine.
What Is Duloxetin Teva B.V. and What Is It Used For?
Duloxetin Teva B.V. is a generic formulation containing the active substance duloxetine hydrochloride, manufactured by Teva B.V. Duloxetine belongs to a class of medications known as serotonin-norepinephrine reuptake inhibitors (SNRIs). These medications work by blocking the reuptake (reabsorption) of two key neurotransmitters—serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (noradrenaline)—at the synaptic cleft in the central nervous system. By preventing these neurotransmitters from being recycled back into the presynaptic neuron, duloxetine effectively increases their concentration and availability in the brain and descending pain pathways of the spinal cord.
Serotonin is a neurotransmitter that plays a critical role in regulating mood, appetite, sleep, and emotional processing. Low serotonin levels have been consistently linked to depression and anxiety disorders. Norepinephrine, on the other hand, is involved in alertness, concentration, energy, and the body’s stress response. It also plays an important role in descending inhibitory pain pathways—neural circuits that travel from the brain down through the spinal cord and help modulate (reduce) pain signals before they reach conscious awareness. This dual action on both serotonin and norepinephrine is what gives duloxetine its unique therapeutic profile, making it effective for both psychiatric conditions and chronic pain syndromes.
The mechanism of action explains why duloxetine has been approved for a broader range of indications than many other antidepressants. At higher serotonin-to-norepinephrine reuptake inhibition ratios, duloxetine helps alleviate depressive and anxious symptoms. At the spinal cord level, the increased availability of both neurotransmitters enhances descending pain inhibition, which is particularly relevant for conditions like diabetic neuropathy and fibromyalgia where central sensitization (an amplification of pain signals in the nervous system) plays a major role in symptom generation.
Duloxetin Teva B.V. is approved for the following indications in adults:
- Major Depressive Disorder (MDD): Duloxetine is effective for the acute and maintenance treatment of MDD. In pivotal clinical trials, duloxetine 60 mg once daily demonstrated statistically significant superiority over placebo in reducing depressive symptoms as measured by the Hamilton Depression Rating Scale (HAMD-17) and the Montgomery-Åsberg Depression Rating Scale (MADRS). Response rates (defined as ≥50% reduction in HAMD-17 score) ranged from 50% to 65% in duloxetine-treated patients versus 30% to 40% for placebo. Remission rates (HAMD-17 ≤7) were approximately 40% to 50%. The antidepressant effect typically begins within 1 to 2 weeks, with full therapeutic benefit usually achieved by 4 to 6 weeks of treatment.
- Generalized Anxiety Disorder (GAD): Duloxetine is approved for the treatment of GAD in adults. Clinical studies showed that duloxetine 60–120 mg daily produced significant reductions in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale (HAM-A), with improvements observed as early as week 1 or 2. Duloxetine has been shown to improve not only the psychological symptoms of anxiety (worry, apprehension, tension) but also the physical symptoms (muscle tension, restlessness, fatigue) that frequently accompany GAD.
- Diabetic Peripheral Neuropathic Pain: Duloxetine 60 mg once daily is effective for the management of neuropathic pain associated with diabetes. In randomized controlled trials, duloxetine produced clinically meaningful reductions in 24-hour average pain severity compared with placebo, with approximately 50% of patients achieving at least a 30% reduction in pain. The analgesic effect is generally apparent within the first week of treatment and is independent of any effect on mood.
- Fibromyalgia: Duloxetine 60 mg once daily is approved for the management of fibromyalgia in adults. Clinical trials demonstrated significant improvements in pain severity, tender point sensitivity, and overall global assessment scores. The Fibromyalgia Impact Questionnaire (FIQ) scores also improved significantly in duloxetine-treated patients. The pain-relieving effect of duloxetine in fibromyalgia is thought to be mediated primarily through enhancement of descending inhibitory pain pathways in the spinal cord.
- Chronic Musculoskeletal Pain: In some regulatory jurisdictions, duloxetine is also indicated for chronic musculoskeletal pain, including chronic lower back pain and chronic osteoarthritis pain. Studies in these populations have shown that duloxetine 60 mg daily significantly reduces pain intensity compared with placebo, with benefits typically evident within 1 to 2 weeks.
As a generic medicine, Duloxetin Teva B.V. has demonstrated bioequivalence to the originator product (Cymbalta), meaning it delivers the same amount of active substance into the bloodstream at the same rate. This ensures that Duloxetin Teva B.V. provides the same therapeutic efficacy, safety profile, and quality as the original branded formulation. The availability of generic duloxetine has significantly improved patient access to this important medication worldwide.
SNRIs like duloxetine differ from selective serotonin reuptake inhibitors (SSRIs) in that they inhibit the reuptake of both serotonin and norepinephrine, rather than serotonin alone. This dual mechanism provides broader therapeutic coverage, particularly for conditions involving both mood disturbance and pain. Other medications in the SNRI class include venlafaxine, desvenlafaxine, milnacipran, and levomilnacipran, though each has somewhat different selectivity ratios and clinical profiles.
What Should You Know Before Taking Duloxetin Teva B.V.?
Contraindications
There are several situations in which duloxetine must not be used. These absolute contraindications are based on evidence of serious harm and should be strictly observed:
- Hypersensitivity: Do not take Duloxetin Teva B.V. if you are allergic to duloxetine hydrochloride or any of the other ingredients in the capsule. Allergic reactions may include rash, itching, swelling, and in rare cases, anaphylaxis.
- MAO inhibitors: Duloxetine must not be used together with monoamine oxidase (MAO) inhibitors (such as phenelzine, tranylcypromine, isocarboxazid, moclobemide, or the antibiotic linezolid) or within 14 days of stopping an MAO inhibitor. Conversely, at least 5 days must pass after stopping duloxetine before starting an MAO inhibitor. The combination can cause serotonin syndrome, a potentially life-threatening condition characterized by agitation, confusion, rapid heartbeat, high blood pressure, dilated pupils, muscle twitching, high fever, and in severe cases, seizures and loss of consciousness.
- Severe hepatic impairment: Duloxetine is extensively metabolized by the liver (primarily through CYP1A2 and CYP2D6 enzymes). Patients with severe liver disease (e.g., cirrhosis, Child-Pugh class C) have markedly elevated plasma levels of duloxetine and a significantly increased risk of hepatotoxicity. Duloxetine is contraindicated in these patients.
- Severe renal impairment: Duloxetine is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), as the drug and its metabolites accumulate to potentially toxic levels due to reduced clearance.
- Uncontrolled narrow-angle glaucoma: Duloxetine can cause mydriasis (pupil dilation) due to its noradrenergic effects. In patients with anatomically narrow drainage angles in the eye who have not undergone an iridotomy, this mydriasis can precipitate an acute attack of angle-closure glaucoma, potentially leading to permanent vision loss.
- Potent CYP1A2 inhibitors: Concomitant use with potent inhibitors of the CYP1A2 enzyme, such as fluvoxamine, ciprofloxacin, or enoxacin, is contraindicated because these drugs can increase duloxetine plasma concentrations by up to 6-fold, significantly raising the risk of dose-dependent adverse effects.
Warnings and Precautions
Antidepressants, including duloxetine, may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25 years) during the initial months of treatment. Closely monitor all patients starting duloxetine for worsening depression, unusual changes in behavior, or suicidal ideation. Report any concerns to your healthcare provider immediately. This risk must be balanced against the clinical need for treatment, as untreated depression itself carries a risk of suicide.
Before starting treatment with Duloxetin Teva B.V., discuss the following important considerations with your healthcare provider:
- Hepatotoxicity: Duloxetine has been associated with cases of liver injury, including elevated liver enzymes (transaminases), jaundice, and, in rare cases, hepatitis and liver failure. Patients with pre-existing liver disease, heavy alcohol use, or those taking other hepatotoxic medications are at increased risk. Liver function should be monitored, and duloxetine should be discontinued if jaundice or significant liver enzyme elevations occur.
- Serotonin syndrome: When used in combination with other serotonergic medications (other SSRIs, SNRIs, triptans, tramadol, tryptophan, St. John’s Wort, lithium, or fentanyl), duloxetine can contribute to serotonin syndrome. Symptoms include agitation, hallucinations, rapid heartbeat, hyperthermia, muscle rigidity, tremor, and gastrointestinal disturbance. If serotonin syndrome is suspected, all serotonergic agents should be discontinued immediately and supportive care initiated.
- Bleeding risk: Serotonin plays a role in platelet aggregation. Duloxetine may increase the risk of bleeding events, particularly when used with anticoagulants (warfarin, heparin), antiplatelet agents (aspirin, clopidogrel), or nonsteroidal anti-inflammatory drugs (NSAIDs). Patients should be advised to report any unusual bruising or bleeding.
- Blood pressure elevation: Duloxetine can cause sustained increases in blood pressure. Blood pressure should be measured before starting treatment and periodically during therapy. Patients with pre-existing hypertension should be monitored closely, and treatment should be reconsidered if sustained blood pressure elevation is observed.
- Hyponatremia: Cases of hyponatremia (low sodium levels in the blood) have been reported, particularly in elderly patients and those taking diuretics. Symptoms may include headache, difficulty concentrating, memory impairment, confusion, weakness, and in severe cases, falls and seizures. Sodium levels should be checked if symptoms suggestive of hyponatremia develop.
- Mania/hypomania: Duloxetine should be used with caution in patients with a history of mania or bipolar disorder, as it may trigger manic episodes. If a patient enters a manic phase, duloxetine should be discontinued.
- Seizures: Duloxetine should be used with caution in patients with a history of seizure disorder, as it may lower the seizure threshold.
Pregnancy and Breastfeeding
Duloxetine should only be used during pregnancy if the potential benefit clearly justifies the potential risk to the fetus. There are no adequate and well-controlled studies of duloxetine in pregnant women. However, epidemiological data and case reports have identified potential risks associated with SNRI exposure during pregnancy.
Neonates exposed to SNRIs, including duloxetine, late in the third trimester have in some cases developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. These complications can include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of the SNRI or a drug discontinuation syndrome in the neonate. In some cases, the clinical picture is consistent with neonatal serotonin syndrome.
If you are pregnant or planning to become pregnant, discuss the risks and benefits of continuing or discontinuing duloxetine with your doctor. Abrupt discontinuation of duloxetine during pregnancy should be avoided due to the risk of withdrawal symptoms in both the mother and potentially the neonate. Untreated maternal depression also carries risks for the pregnancy, including preterm birth, low birth weight, and postnatal complications, so the decision should always weigh the risks of medication against the risks of untreated illness.
Duloxetine is excreted in human breast milk. Based on a study in lactating women, the estimated daily infant dose is approximately 0.14% of the maternal dose. Because the safety of duloxetine in infants is not well established, a decision should be made whether to discontinue breastfeeding or to discontinue duloxetine, considering the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Elderly Patients
Elderly patients may be more susceptible to certain side effects of duloxetine, including hyponatremia, dizziness, and falls. The pharmacokinetics of duloxetine are not significantly altered in elderly patients based on age alone, so no dose adjustment is required solely due to age. However, caution is advised, particularly in patients over 65 years, and a lower starting dose may be considered. Kidney function, liver function, and electrolyte balance should be assessed before and during treatment.
Driving and Operating Machinery
Duloxetine may cause drowsiness, dizziness, or blurred vision in some patients, particularly during the initial weeks of treatment or after dose adjustments. Patients should exercise caution when driving or operating machinery until they are reasonably confident that duloxetine does not adversely affect their ability to engage in these activities. If you experience significant sedation or dizziness, avoid potentially hazardous tasks until these symptoms resolve.
How Does Duloxetin Teva B.V. Interact with Other Drugs?
Understanding drug interactions is essential for the safe and effective use of duloxetine. Because duloxetine is extensively metabolized by the liver through CYP1A2 and CYP2D6 enzymes, and because it acts on serotonin and norepinephrine systems, there are several clinically significant interactions to be aware of. Additionally, duloxetine is a moderate inhibitor of CYP2D6, which means it can increase the blood levels of other medications that are metabolized through this pathway.
Major Interactions
| Drug / Drug Class | Mechanism | Risk / Effect | Action |
|---|---|---|---|
| MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue) | Blocked MAO + blocked reuptake = massive serotonin accumulation | Life-threatening serotonin syndrome | Contraindicated. 14-day washout required. |
| Fluvoxamine | Potent CYP1A2 inhibitor increases duloxetine levels ~6-fold | Severe dose-dependent toxicity | Contraindicated. Do not co-administer. |
| Ciprofloxacin / Enoxacin | Potent CYP1A2 inhibitors increase duloxetine levels significantly | Increased adverse effects | Avoid combination or use with extreme caution. |
| Thioridazine | CYP2D6 inhibition by duloxetine increases thioridazine levels | QT prolongation, cardiac arrhythmias | Contraindicated. Do not co-administer. |
| Other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, tryptophan, St. John’s Wort) | Additive serotonergic activity | Serotonin syndrome | Use with caution. Monitor for symptoms. |
Moderate Interactions
| Drug / Drug Class | Mechanism | Risk / Effect | Action |
|---|---|---|---|
| Warfarin and other anticoagulants | Serotonin depletion in platelets + possible pharmacokinetic interaction | Increased bleeding risk, elevated INR | Monitor INR closely when starting or stopping duloxetine. |
| NSAIDs / Aspirin | Impaired platelet serotonin + NSAID gastropathy | Increased risk of GI bleeding | Use lowest effective dose. Consider gastroprotection. |
| CYP2D6 substrates (metoprolol, desipramine, atomoxetine, tolterodine, risperidone) | Duloxetine inhibits CYP2D6, raising substrate levels | Increased effects and side effects of the substrate drug | Consider dose reduction of CYP2D6 substrate. |
| Alcohol | Both hepatotoxic; CNS depression additive | Liver damage, excessive sedation | Avoid or minimize alcohol use during treatment. |
| Lithium | Additive serotonergic effect | Serotonin syndrome | Monitor closely. Adjust doses as needed. |
| Antihypertensives | Duloxetine may increase blood pressure | Reduced antihypertensive efficacy | Monitor blood pressure regularly. |
Patients should always inform their healthcare provider about all medications they are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. Even seemingly harmless supplements like St. John’s Wort (Hypericum perforatum) can interact dangerously with duloxetine by increasing serotonergic activity. Keeping an up-to-date medication list and sharing it with every healthcare provider you see is an essential safety practice.
Cigarette smoking induces CYP1A2 enzyme activity, which can reduce duloxetine plasma concentrations by approximately 50%. If a patient who smokes begins or stops smoking during duloxetine treatment, dose adjustments may be necessary. Conversely, if a patient stops smoking, duloxetine levels may rise, potentially increasing side effects. Discuss any changes in smoking habits with your doctor.
What Is the Correct Dosage of Duloxetin Teva B.V.?
The dosage of Duloxetin Teva B.V. depends on the condition being treated, the patient’s overall health, and individual response to the medication. Duloxetine gastro-resistant capsules should be swallowed whole with water and should not be crushed, chewed, or opened, as the gastro-resistant coating protects the drug from degradation by stomach acid. The capsules can be taken with or without food, although taking them with food may help reduce nausea in sensitive patients.
Adults
Major Depressive Disorder
Starting dose: 30 mg once daily for at least 2 weeks
Therapeutic dose: 60 mg once daily
Maximum dose: 120 mg daily (as a single dose or divided into two doses)
Duration: Continue for at least 6 months after remission to prevent relapse. Longer maintenance may be warranted in patients with recurrent depression.
Generalized Anxiety Disorder
Starting dose: 30 mg once daily (may start at 60 mg in some patients)
Therapeutic dose: 60 mg once daily
Maximum dose: 120 mg daily
Duration: Treatment should continue for several months. The need for continued treatment should be reassessed regularly.
Diabetic Peripheral Neuropathic Pain
Starting dose: 60 mg once daily (may start at 30 mg for tolerability)
Therapeutic dose: 60 mg once daily
Maximum dose: 60 mg daily (doses above 60 mg have not shown additional benefit and are associated with more adverse effects)
Response evaluation: Assess after 2 months. If response is inadequate, continued treatment is unlikely to be beneficial.
Fibromyalgia
Starting dose: 30 mg once daily for 1 week
Therapeutic dose: 60 mg once daily
Maximum dose: 60 mg daily
Duration: The therapeutic benefit should be reassessed regularly. Pain relief is generally maintained with continued treatment, but the need for ongoing therapy should be evaluated periodically.
Chronic Musculoskeletal Pain
Starting dose: 30 mg once daily for 1 week
Therapeutic dose: 60 mg once daily
Maximum dose: 60 mg daily
Note: Available as an approved indication in some regulatory jurisdictions (e.g., FDA-approved in the US for chronic lower back pain and chronic osteoarthritis pain).
Children and Adolescents
Duloxetin Teva B.V. is not recommended for use in children and adolescents under 18 years of age for the treatment of depression or anxiety. The safety and efficacy of duloxetine in pediatric patients have not been established for most indications, and antidepressants carry an increased risk of suicidal thoughts and behavior in this age group. Healthcare providers should consider age-appropriate treatment alternatives for pediatric patients.
Elderly Patients
No dose adjustment is routinely required based on age alone. However, elderly patients should be treated with caution due to increased susceptibility to side effects such as hyponatremia, dizziness, and falls. A lower starting dose of 30 mg once daily may be prudent, with gradual titration based on tolerability. Renal and hepatic function should be assessed before initiating treatment in elderly patients.
Renal and Hepatic Impairment
Mild to moderate renal impairment (creatinine clearance 30–80 mL/min): No dose adjustment is necessary, but caution is advised.
Severe renal impairment (creatinine clearance <30 mL/min): Duloxetine is contraindicated.
Mild hepatic impairment (Child-Pugh A): No dose adjustment is necessary.
Moderate hepatic impairment (Child-Pugh B): A lower starting dose and slower dose escalation should be considered.
Severe hepatic impairment (Child-Pugh C): Duloxetine is contraindicated.
Missed Dose
If you forget to take a dose of Duloxetin Teva B.V., take it as soon as you remember on the same day. If it is almost time for your next dose (within approximately 6 hours), skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider using a daily alarm or pill organizer to help maintain a consistent dosing schedule.
Overdose
In case of suspected overdose, seek emergency medical attention immediately. There is no specific antidote for duloxetine overdose. Treatment is supportive and symptom-based. Symptoms of overdose may include drowsiness, serotonin syndrome, seizures, vomiting, and rapid heartbeat (tachycardia). In clinical trials and post-marketing experience, fatalities have been reported with duloxetine overdose, primarily in combination with other drugs and/or alcohol. Activated charcoal may be considered if administered early after ingestion.
Stopping Treatment
Duloxetine should never be stopped abruptly. Sudden discontinuation can lead to a discontinuation syndrome with symptoms including dizziness, headache, nausea, diarrhea, paresthesia (tingling or numbness), irritability, vomiting, insomnia, anxiety, hyperhidrosis (excessive sweating), fatigue, and characteristic electric shock-like sensations often described as “brain zaps.” These symptoms typically appear within days of stopping the medication and may last for several weeks.
To minimize discontinuation symptoms, duloxetine should be gradually tapered over a period of at least 2 weeks. A common tapering strategy is to reduce the dose from 60 mg to 30 mg daily for 2 weeks before stopping completely. Some patients may require even slower tapering schedules, particularly those who have been on duloxetine for a long time or who are sensitive to discontinuation effects. If intolerable withdrawal symptoms occur during the taper, your doctor may suggest returning to the previously prescribed dose and then reducing more slowly.
What Are the Side Effects of Duloxetin Teva B.V.?
Like all medicines, Duloxetin Teva B.V. can cause side effects, although not everybody gets them. Most side effects are dose-dependent and tend to occur more frequently during the first few weeks of treatment before gradually diminishing as the body adjusts to the medication. The side effects listed below are classified by their frequency of occurrence based on data from clinical trials involving thousands of patients.
Very Common
Affects more than 1 in 10 patients
- Nausea (most frequent, ~23% of patients; usually improves within 1–2 weeks)
- Headache
- Dry mouth (xerostomia)
- Drowsiness (somnolence)
Common
Affects 1 in 10 to 1 in 100 patients
- Dizziness
- Constipation
- Diarrhea
- Fatigue
- Decreased appetite and weight loss
- Insomnia or disturbed sleep
- Increased sweating (hyperhidrosis)
- Abdominal pain
- Vomiting
- Tremor
- Blurred vision
- Erectile dysfunction
- Decreased libido
- Delayed ejaculation
- Hot flushes
- Muscle tension or spasms
- Palpitations
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Weight gain
- Teeth grinding (bruxism)
- Muscle twitching (myoclonus)
- Feeling jittery or restless (akathisia)
- Difficulty urinating (urinary hesitation)
- Abnormal taste (dysgeusia)
- Tinnitus (ringing in the ears)
- Night sweats
- Elevated blood pressure
- Skin rash
- Cold extremities
- Abnormal orgasm or anorgasmia
- Elevated liver enzymes (ALT, AST)
Rare
Affects 1 in 1,000 to 1 in 10,000 patients
- Serotonin syndrome
- Hepatitis and jaundice
- Liver failure (very rare)
- Hyponatremia (low blood sodium)
- Severe allergic reactions (anaphylaxis, angioedema)
- Stevens-Johnson syndrome
- Seizures
- Mania or hypomania
- Angle-closure glaucoma
- Gastrointestinal bleeding
- Galactorrhea (abnormal breast milk production)
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Frequency Not Known
Reported in post-marketing surveillance
- Cutaneous vasculitis (inflammation of skin blood vessels)
- Extrapyramidal symptoms (movement disorders)
- Interstitial lung disease and eosinophilic pneumonia
Many of the common side effects of duloxetine, particularly nausea and drowsiness, tend to decrease in severity within the first 1 to 2 weeks of treatment as the body adjusts. Taking duloxetine with food can help reduce gastrointestinal side effects. If side effects persist or become bothersome, consult your doctor before making any changes to your treatment. In many cases, a dosage adjustment or a change in the timing of administration can significantly improve tolerability.
Sexual dysfunction (decreased libido, erectile dysfunction, delayed ejaculation, difficulty achieving orgasm) is a well-recognized side effect of duloxetine and other serotonergic antidepressants. These effects occur in approximately 5–15% of patients depending on the specific symptom. Patients should be aware that sexual side effects may not always resolve with continued treatment and should discuss concerns openly with their healthcare provider, as treatment adjustments or additional interventions may be helpful.
If you experience any side effects not listed here, or if you are concerned about a side effect, talk to your doctor or pharmacist. You can also report side effects to your national pharmacovigilance authority (e.g., the Medicines and Healthcare products Regulatory Agency in the UK, the FDA MedWatch program in the US, or the EMA in Europe).
How Should You Store Duloxetin Teva B.V.?
Proper storage of duloxetine capsules is essential to maintain their effectiveness and safety. Duloxetine is formulated as gastro-resistant hard capsules, meaning they have a special enteric coating designed to resist dissolution in the acidic environment of the stomach and instead release the active substance in the more alkaline environment of the small intestine. This coating is sensitive to moisture and humidity, so proper storage conditions are particularly important.
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze.
- Moisture protection: Keep the capsules in the original blister packaging or bottle until you are ready to take a dose. The packaging provides an important barrier against environmental moisture. Do not transfer capsules to a pill organizer for extended periods if you live in a humid climate.
- Light protection: While not specifically required, storing the medication away from direct sunlight is good practice.
- Keep out of reach: Store in a secure location out of the sight and reach of children. Duloxetine can be harmful to children if accidentally ingested.
- Expiry date: Do not use Duloxetin Teva B.V. after the expiry date stated on the blister or carton after “EXP.” The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines in household waste or wastewater. Return any unused or expired medication to your pharmacy for safe disposal. This helps protect the environment.
If you notice that capsules have changed in appearance (discoloration, softening, or an unusual odor), do not take them and consult your pharmacist. Damaged capsules may have a compromised enteric coating, which could result in degradation of the active substance in the stomach and reduced therapeutic effectiveness.
What Does Duloxetin Teva B.V. Contain?
Each capsule of Duloxetin Teva B.V. contains duloxetine hydrochloride equivalent to either 30 mg or 60 mg of duloxetine base as the active substance. The gastro-resistant formulation is specifically designed to protect the active substance from degradation by gastric acid and to enable reliable absorption in the duodenum (the first part of the small intestine).
Active substance:
- Duloxetin Teva B.V. 30 mg: Each gastro-resistant hard capsule contains duloxetine hydrochloride equivalent to 30 mg duloxetine.
- Duloxetin Teva B.V. 60 mg: Each gastro-resistant hard capsule contains duloxetine hydrochloride equivalent to 60 mg duloxetine.
Other ingredients (excipients):
- Capsule contents: Sugar spheres (sucrose and maize starch), hypromellose, sucrose, talc, hypromellose phthalate, triethyl citrate, and other standard pharmaceutical excipients that form the gastro-resistant pellets within the capsule.
- Capsule shell: Gelatin, titanium dioxide (E171), indigo carmine (E132) [for certain strengths], iron oxide yellow (E172) [for certain strengths], and other coloring agents depending on the specific capsule strength.
- Printing ink: Shellac, propylene glycol, ammonium hydroxide, potassium hydroxide, and iron oxide black (E172) or titanium dioxide (E171).
The 30 mg capsules are typically distinguished from the 60 mg capsules by their size and color combination. The exact appearance may vary by market. Consult the patient information leaflet included in your specific packaging for a detailed description of the capsules applicable to your market.
Important note about sucrose: Duloxetin Teva B.V. capsules contain sucrose (sugar). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine without consulting their doctor. The amount of sucrose per capsule is small, but this should be taken into account for patients who need to manage their sugar intake.
Frequently Asked Questions About Duloxetin Teva B.V.
Duloxetin Teva B.V. (duloxetine) is a prescription SNRI antidepressant used to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults. It works by increasing serotonin and norepinephrine levels in the brain and spinal cord, which helps regulate mood, reduce anxiety, and decrease pain signals.
Duloxetine may begin to improve sleep, energy, and appetite within the first 1 to 2 weeks of treatment. However, the full antidepressant effect typically takes 4 to 6 weeks. For pain conditions such as diabetic neuropathy and fibromyalgia, some improvement may be noticed within the first week, but maximum pain relief usually requires 2 to 4 weeks. It is important to continue taking the medication as prescribed, even if you do not notice immediate improvement.
No. Duloxetine should never be stopped abruptly because of the risk of discontinuation syndrome. Symptoms can include dizziness, headache, nausea, irritability, electric shock-like sensations (“brain zaps”), insomnia, and diarrhea. Your doctor will create a gradual tapering plan, typically reducing the dose over at least 2 weeks. Some patients may need an even slower taper. If you experience severe withdrawal symptoms during the taper, contact your healthcare provider.
It is strongly recommended to avoid alcohol while taking duloxetine. Both duloxetine and alcohol are metabolized in the liver, and combining them increases the risk of liver damage (hepatotoxicity). Alcohol can also worsen duloxetine’s side effects, including drowsiness and dizziness, and can worsen the symptoms of depression and anxiety. If you have concerns about alcohol consumption, discuss them with your healthcare provider.
Weight changes with duloxetine can go in both directions. In short-term clinical trials (up to 12 weeks), duloxetine was associated with a modest decrease in appetite and small weight loss in some patients. However, in longer-term use, some patients do experience weight gain. The weight gain is generally less pronounced than with some other antidepressants (such as mirtazapine or certain tricyclic antidepressants). If you notice significant weight changes during treatment, discuss this with your doctor.
Duloxetin Teva B.V. is a generic version of the original branded medication Cymbalta. Both contain the same active substance (duloxetine hydrochloride), in the same doses, and in the same pharmaceutical form (gastro-resistant capsules). Duloxetin Teva B.V. has been demonstrated to be bioequivalent to Cymbalta through rigorous testing, meaning it delivers the same amount of active drug into the bloodstream at the same rate. The primary difference is the manufacturer and often the price, with generic formulations typically being more affordable.
References
- European Medicines Agency (EMA). Duloxetine Teva B.V. – Summary of Product Characteristics. EMA/CHMP. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Cymbalta (duloxetine delayed-release capsules) – Prescribing Information. Revised 2024.
- National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline NG222. Published June 2022.
- American Psychiatric Association (APA). Practice Guidelines for the Treatment of Major Depressive Disorder. 3rd ed. 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
- Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;(1):CD007115.
- British National Formulary (BNF). Duloxetine. National Institute for Health and Care Excellence. Updated 2025.
- Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-118.
- Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-2984.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry, Neurology, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Board-certified physicians following GRADE evidence framework
Evidence Standards
Level 1A evidence from systematic reviews, meta-analyses, and randomized controlled trials (Cochrane, Lancet, APA)
Guidelines Followed
WHO, EMA, FDA, NICE NG222, APA Practice Guidelines, BNF
Conflict of Interest: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independently produced with no commercial funding or advertising sponsorship.